OSE Immunotherapeutics Announces Results of 2018 Annual Shareholder Meeting

World News: . []

NANTES, France, June 13, 2018 (GLOBE NEWSWIRE) -- (ISIN:FR0012127173) (Mnémo:OSE) announces that all the resolutions submitted to a vote at the Combined General Shareholders' Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

The results of each resolution voted can be found on the Company’s website in the “Investor Relations – Annual General Meeting” section .

A total of 60 shareholders were present or represented, or voted by mail. Collectively, this group holds 8,219,498 shares (representing 56.92 % of the voting securities) and 12,189,454 voting rights.

During the meeting, Dominique Costantini, Chairman, and Alexis Peyroles, CEO of OSE Immunotherapeutics, provided an overview of the Company’s latest advances and growth strategy.

The recent license and collaboration agreement signed with Boehringer Ingelheim on OSE-172 adds to OSE Immunotherapeutics’ partnership strategy, currently totalling three key strategic and structuring partnerships driving the next steps of the Company’s growth. OSE’s focus remains on the development of its product portfolio, including Tedopi®, currently in Phase 3 development with orphan status designation; and three partnered products (OSE-172 with Boehringer Ingelheim, OSE-127 with Servier, and FR-104 with Janssen Biotech) in various stages of development.

Upcoming milestones for the Company include:Immuno-Oncology:

Autoimmune:

Research & Development:

Click and follow us on Twitter and Linkedln

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.

Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 26 April 2018, including the annual financial report for the fiscal year 2017, available on the OSE Immunotherapeutics’ website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.

More news and information about OSE Immunotherapeutics

Published By:

Globe Newswire: 17:00 GMT Wednesday 13th June 2018

Published: .

Search for other references to "immunotherapeutics" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers